Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump

The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.

White House

More from Pricing Debate

More from Market Access